Biomaterials

UK Medical Device Company Announces Two New Patents Granted by the US Patent and Trademark Office

SIRAKOSS’ patent portfolio encompasses advanced synthetic bone graft technologies which form the company’s product pipeline designed to address the significant clinical need for a fully-synthetic, standalone bone void filler.

Read More

SeaSpine Announces Full Commercial Launch of Vu a∙POD Prime NanoMetalene System

The Vu a•POD Prime NanoMetalene System features a zero-profile, standalone anterior lumbar interbody device that can be configured in a variety of footprint and lordosis combinations to accommodate an individual patient’s pathology.

Read More

Xtant Medical Receives FDA Clearance for the Xsert Lumbar Expandable Interbody System

Xtant Medical develops, manufactures and markets regenerative medicine products and medical devices for domestic and international markets. The Xsert System is an all titanium expandable interbody device that expands in-situ.

Read More

New Orthopedic Stem Cell Therapy Could Grow Cartilage to Avoid Joint Hip Replacement Surgery

Washington University scientists have coaxed stem cells to grow into new cartilage on a 3-D template shaped like the ball of a hip joint. Technique uses 3-D weaving to grow a living hip replacement. The scaffold is covered with cartilage made from stem cells taken from fat beneath the skin.

Read More

DePuy Synthes, Stryker Lead Australian Synthetic Bone Graft Substitute Market with β-TCP Product Lines

The orthopedic biomaterials market in Australia grew due to the entry of major new products and their rapid growth in the period from 2012 to 2014.

Read More

Medtronic, DePuy Synthes, Wright Medical Compete With Local Manufacturers in Asia-Pacific Orthopedic Biomaterials Market

Local Asia-Pacific competitors in the orthopedic biomaterials market such as Seikagaku, Meiji Seika Kaisha and Shin Poong are leading in several biologics segments due to regulatory government support

Read More

French Hyaluronic Acid Viscosupplementation Market in Decline due to Budget Constraints

The European hyaluronic acid viscosupplementation (HA) market was in decline, caused by the lowering of ASPs across many European countries due to health care budget constraints, leading to lower reimbursement rates.

Read More

BIOMATLANTE Obtains Approval to Market New Synthetic Bone Graft Substitutes

BIOMATLANTE announced the CE regulatory approval of EZ CURE™ Strip and EZ CURE Plug, a combination of highly purified collagen Type I with its MBCP™ core technology, to extend its range of synthetic bone graft substitutes.

Read More